Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • Derek Chauvin convicted of murdering George Floyd
    • Xi warns against economic decoupling and calls for new world order
    • Covid vaccines and the race to understand blood clots
    • MI5 warns of spy threat from professional networking sites
    • Armin Laschet to run as candidate to succeed Merkel after rival backs out
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Derek Chauvin convicted of murdering George Floyd
    • Berkshire directors rebuked over pay for likely Buffett successors
    • Xi warns against economic decoupling and calls for new world order
    • Netflix shares slide on angst over subscriber growth
    • Corporate America’s woke moment won’t last
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Leaked Super League plans reveal goal of US-style football finances
    • Super League plan collapses as more clubs pull out
    • How Credit Suisse rolled the dice on risk management — and lost
    • Berkshire directors rebuked over pay for likely Buffett successors
    • Super League rebels shift the goalposts of European football
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • US government bond investors left bewildered by ‘bonkers’ market move
    • Wirecard inquiry: Germany’s political and financial elite exposed
    • Whether it’s football or chips, let’s be upfront about our national interests
    • Wall Street stocks have biggest daily drop in a month
    • Huarong debacle tests Beijing’s resolve to bail out state groups
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Super League would break football’s essential promise
    • Corporate America’s woke moment won’t last
    • Robinhood traders might have had a point on Hertz
    • Economic recovery masks the dangers of a divided world
    • TikTok’s India ban should be a warning for tech companies
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • The new frontiers of hybrid work take shape
    • Get ready for the new politics of resentment in the office
    • Gaming inspires new worlds of virtual work
    • Watch this slam dunk example of great management
    • Ethiopia’s human rights chief: ‘It’s not an easy ride for us. We get a lot of heat ’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • VTubers and the women behind the masks
    • Scotland faces up to life after oil
    • China’s keyboard warriors like to fight . . .  each other
    • Anne Boden: ‘Cash will disappear’
    • The vanishing billionaire: how Jack Ma fell foul of Xi Jinping
  • How to Spend It
  • Sign In
  • Subscribe
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Hannah Kuchler

Global Pharmaceuticals Correspondent
Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 21 April, 2021
    Roche Holding AG
    Covid-19 test demand boosts Roche

    Swiss pharmaceutical company reports 55% jump in diagnostic sales

  • Friday, 16 April, 2021
    News in-depthGlaxoSmithKline PLC
    Pipeline pressure and Elliott’s stake have GSK in a spin

    CEO Emma Walmsley under scrutiny as British drugmaker’s cupboard looks increasingly bare

  • Thursday, 15 April, 2021
    GlaxoSmithKline PLC
    Hedge fund Elliott builds multibillion-pound stake in GSK

    Activist group’s investment comes as UK drugmaker’s performance lags behind rivals 

  • Wednesday, 14 April, 2021
    Covid-19 vaccines
    EU bets on BioNTech/Pfizer jab as Danes stop giving AstraZeneca

    Brussels puts focus on mRNA vaccines amid concern over rare blood clots linked to other shots

  • Wednesday, 14 April, 2021
    Covid-19 vaccines
    AstraZeneca vaccine elicits stronger T-cell response in elderly than Pfizer jab

    Study adds to evidence in favour of spacing out doses to fight Covid

  • Tuesday, 13 April, 2021
    Covid-19 vaccines
    Can mixing Covid vaccines work?

    Scientists are testing the risks and advantages of offering a different shot for second and third doses

  • Tuesday, 13 April, 2021
    Covid-19 vaccines
    J&J delays vaccine rollout in Europe after US health agencies call for pause

    CDC and FDA recommendation comes after reports of ‘rare and severe’ blood clots

  • Saturday, 10 April, 2021
    Covid-19 vaccines
    UK-backed vaccine maker warns of export restrictions in IPO filing

    Paris-listed Valneva is seeking to raise $100m in American depositary shares

  • Friday, 9 April, 2021
    Vaccitech
    Vaccitech warns of blood clot risk in IPO filing

    Oxford university spinout behind AstraZeneca Covid-19 jab pushes ahead with US listing

  • Promoted Content
  • Friday, 9 April, 2021
    AstraZeneca PLC
    AstraZeneca cuts this week’s vaccine deliveries to EU by half

    Drugmaker slashes total because of delays in testing

  • Friday, 9 April, 2021
    Q&ACovid-19 vaccines
    How is the Covid vaccines rollout going? Q&A

    FT science editor Clive Cookson and pharma correspondent Hannah Kuchler answer your questions

  • Thursday, 8 April, 2021
    Coronavirus treatment
    Experts back UK age limit for rollout of AstraZeneca vaccine

    Decision to restrict jab only for people under 30 contrasts with tougher stance in other countries

  • Wednesday, 7 April, 2021
    Biotech
    Biotech start-up behind AstraZeneca vaccine files for US listing

    Vaccitech IPO likely to be seen as a loss for London as UK seeks to be hub for life sciences investment

  • Tuesday, 6 April, 2021
    Covid-19 vaccines
    French Valneva vaccine shows positive early trial results

    Biotech company’s jab could be used to tackle Covid-19 virus variants

  • Thursday, 25 March, 2021
    AstraZeneca PLC
    Disputes leave AstraZeneca boss with chronic vaccine headache

    Questions mount over whether Soriot’s dash and drive, which enthral investors, have resulted in missteps

  • Thursday, 25 March, 2021
    Covid-19 vaccines
    AstraZeneca revises down efficacy rate for US Covid vaccine trial

    New assessment lowers figure to 76% after criticism that earlier data was incomplete

  • Wednesday, 24 March, 2021
    GlaxoSmithKline PLC
    GSK says Trump vaccine tsar accused of sexual harassment

    Moncef Slaoui forced out as chair of the board of drugmaker’s subsidiary Galvani Bioelectronics

  • Tuesday, 23 March, 2021
    News in-depthCovid-19 vaccines
    AstraZeneca’s shot at redemption sows further confusion

    Dispute with independent scientists overseeing US trial is latest blow to tortured rollout

  • Tuesday, 23 March, 2021
    Covid-19 vaccines
    AstraZeneca to revise vaccine trial data after monitors raise alarm

    Independent board tells US authorities outdated information may have provided ‘incomplete view’ of efficacy

  • Friday, 19 March, 2021
    Covid-19 vaccines
    Push to make Covid vaccines causes US drug shortages

    Pfizer warns of supply interruptions as other pharma groups struggle for materials

  • Wednesday, 17 March, 2021
    Covid-19 vaccines
    NHS warns of ‘significant reduction’ in vaccine supplies

    Delays to jabs for under-50s but Hancock insists programme on course to reach all UK adults by end of July

  • Wednesday, 17 March, 2021
    Biotech
    Biotech start-up behind AstraZeneca jab raises $168m

    Vaccitech will seek to use similar technology to treat other infectious diseases and cancer

  • Wednesday, 17 March, 2021
    Covid-19 vaccines
    AstraZeneca and Catalent defend Covid vaccine manufacturing process

    Pharma giant and key supplier say ‘every batch’ is made to same standards following EMA blood clot inquiry

  • Tuesday, 16 March, 2021
    US opioid epidemic
    Sackler family offers to pay $4.3bn in bankruptcy settlement

    Owners of opioid maker Purdue Pharma pledge extra money to win over US states that rejected deal

  • Monday, 15 March, 2021
    ExplainerCovid-19 vaccines
    Blood clot fears and the Oxford-AstraZeneca vaccine: what we know

    No evidence of a link but several European countries have suspended the Covid jab

Previous You are on page 1 Next

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

FT LiveShare News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & Tenders
Executive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School Rankings
Enterprise ToolsNews feedNewslettersCurrency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2021. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Graphics
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In